RESUMO
OBJECTIVES: Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in Western countries. No studies have examined the cost-effectiveness of screening its advanced form, nonalcoholic steatohepatitis (NASH). METHODS: We performed a cost-utility analysis of annual noninvasive screening strategies using third-party payer perspective in a general population in comparison to screening a high-risk obese or diabetic population. Screening algorithms involved well-studied techniques, including NAFLD fibrosis score, transient elastography (TE), and acoustic radiation force impulse (ARFI) imaging for detecting advanced fibrosis (≥ F3); and plasma cytokeratin (CK)-18 for NASH detection. Liver biopsy and magnetic resonance elastography (MRE) were compared as confirmation methods. Canadian dollar (CAD or C$) costs were adjusted for inflation and discounted at 5%. Incremental cost-effectiveness ratio (ICER) of ≤C$ 50,000 was considered cost-effective. RESULTS: Compared with no screening, screening with NAFLD fibrosis score/TE/CK-18 algorithm with MRE as confirmation for advanced fibrosis had an ICER of C$ 26,143 per quality-adjusted life year (QALY) gained. Screening in high-risk obese or diabetic populations was more cost-effective, with an ICER of C$ 9,051 and C$ 7,991 per quality-adjusted life-year (QALY) gained, respectively. Liver biopsy confirmation was not found to be cost-effective. CONCLUSIONS: Our model suggests that annual NASH screening in high-risk obese or diabetic populations can be cost-effective. KEY POINTS: ⢠This cost-utility analysis suggests that screening for nonalcoholic steatohepatitis may be cost-effective. ⢠In particular, screening of high-risk obese or diabetic populations is more cost-effective. ⢠Magnetic resonance elastography was more cost-effective to confirm disease compared to biopsy. ⢠More studies are needed to determine quality of life in nonalcoholic steatohepatitis. ⢠More management strategies for nonalcoholic steatohepatitis are also needed.
Assuntos
Hepatopatia Gordurosa não Alcoólica/diagnóstico , Biópsia , Canadá , Análise Custo-Benefício , Diabetes Mellitus Tipo 2/complicações , Diabetes Mellitus Tipo 2/economia , Diagnóstico Precoce , Técnicas de Imagem por Elasticidade/métodos , Humanos , Cirrose Hepática/diagnóstico , Cirrose Hepática/economia , Cadeias de Markov , Pessoa de Meia-Idade , Hepatopatia Gordurosa não Alcoólica/economia , Obesidade/complicações , Obesidade/economia , Avaliação de Resultados da Assistência ao Paciente , Qualidade de Vida , Anos de Vida Ajustados por Qualidade de Vida , Fatores de RiscoRESUMO
AIMS: To evaluate the health care burden of chronic hepatitis C (CHC) in French hospitals. METHODS: All hospital stays with CHC ICD-10 code were extracted from the 2009 French hospital discharge database and classified in five groups: non-complicated CHC, liver cirrhosis (CIR), hepatocarcinoma (HCC), liver transplantation (LT) and unclassified. Hospital costs were calculated according to the French official prices and expressed in 2010 euro. The economic analysis was carried out from the Social Security point of view. RESULTS: Twenty-seven thousand two hundred and fifty-eight of the 68,683 hospital stays with CHC ICD-10 code corresponding to 15,482 patients were considered as directly related to HCV: 52% for non-complicated CHC, 33% for CIR, 11% for HCC, 2% for LT and 2% unclassified. The total cost of hospital stays for CHC and its complications was estimated at 65,956,938 . Almost half (47%) of total costs were attributable to CIR while HCC and LT contributed to 18% and 19%, respectively. CONCLUSION: This first analysis of the French hospital discharge database focused on CHC brings new and essential information. It shows that 84% of HCV-related hospital costs are attributable to advanced liver diseases. Together with more efficient therapies, enhancing screening and access to treatment policies could substantially relieve the hospital burden of CHC.